Trial
NCT01425970
Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Bristol-Myers Squibb
Collaborators
—
Condition
Hepatitis C
Intervention
INX-08189
Why stopped
Termination of study was due to safety reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-11-04